Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chubb
Dow
Teva
Express Scripts
Queensland Health
Argus Health
US Army
McKesson

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203491

« Back to Dashboard

NDA 203491 describes ILEVRO, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ILEVRO profile page.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.
Summary for 203491
Tradename:ILEVRO
Applicant:Novartis Pharms Corp
Ingredient:nepafenac
Patents:4
Therapeutic Class:Ophthalmic Agents
Pharmacology for NDA: 203491
Suppliers and Packaging for NDA: 203491
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491 NDA Alcon Laboratories, Inc. 0065-1750 N 0065-1750-07
ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491 NDA Alcon Laboratories, Inc. 0065-1750 N 0065-1750-08

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION/DROPS;OPHTHALMICStrength0.3%
Approval Date:Oct 16, 2012TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jul 17, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Jun 8, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Mar 31, 2032Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Accenture
McKesson
Cipla
UBS
Julphar
McKinsey
Covington
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.